Related Experiment Video
Updated: May 27, 2025
06:21
Adaptable Angled Stereotactic Approach for Versatile Neuroscience Techniques
Published on: May 7, 2020
4.9K
GLP-1 Receptor Agonists: Beyond Diabetes-What the Neurosurgeon Needs to Know
Hael Abdulrazeq1,2, Mazen Taman1, Rohaid Ali1,2
1The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Neurosurgery Practice
|February 17, 2025
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) require careful perioperative management by neurosurgeons due to potential side effects. Emerging research suggests benefits for substance use disorders and neurodegenerative conditions.
Area of Science:
- Pharmacology
- Neurosurgery
- Anesthesiology
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weight management, showing benefits in glycemic control and cardiovascular health.
- As patient numbers rise, neurosurgeons need awareness of perioperative considerations and side effects associated with GLP-1 RAs.
Purpose of the Study:
- To inform neurosurgeons about the perioperative management of GLP-1 RAs.
- To review existing literature on potential neurosurgical applications and benefits of GLP-1 RAs.
Main Methods:
- A qualitative literature review was conducted using PubMed and Embase.
- Keywords included GLP-1 RAs adverse events, anesthesia, substance use disorders, addiction, functional neurosurgery, nervous system rehabilitation, and spinal cord injury.
Main Results:
- Recent American Society of Anesthesiologists guidance emphasizes tailored management of GLP-1 RAs for surgical patients.
- GLP-1 RAs show potential benefits in substance use disorders, neural protection, rehabilitation, and neurodegenerative diseases like Alzheimer's.
Conclusions:
- Neurosurgeons must understand perioperative management of GLP-1 RAs.
- Clinical and preclinical data suggest GLP-1 RAs may influence the management of conditions relevant to neurosurgery.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
01:06Oral Hypoglycemic Agents: Glinides
131
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
131
01:11Local Anesthetics: Clinical Application as Spinal Anesthesia
570
Spinal anesthetics are given during lower abdomen and limb surgeries to block sensory and motor neurons. They are administered in the mid to low lumbar regions, primarily acting on the cauda equina's nerve roots. The blockade level depends on the local anesthetic (LA) concentration. Usually, low LA concentrations are sufficient to block sensory fibers, while only high LA concentrations block motor fibers. Other factors like injection volume and speed, the patient's posture, and the drug...
570
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
204
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
204
01:29Drug Delivery: Parenteral Route
374
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
374
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
672
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
672